Defining the molecular basis of type 2 diabetes predisposition through targeted...
Defining the molecular basis of type 2 diabetes predisposition through targeted sequencing of the CREBBP interacting gene network
Type 2 diabetes (T2D) represents a major challenge to global health. In recent years, over 60 genetic loci have been confidently implicated in T2D predisposition: however, there has been only limited progress in defining the biolo...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
GENE TARGET T2D
General and targeted approaches to unravel the molecular cau...
2M€
Cerrado
3D-ADAPT
Analysis of tridimensional changes caused by type 2 Diabetes...
158K€
Cerrado
Reg-Seq
Functional genomics of non coding mutations in regulatory re...
2M€
Cerrado
GEPIDIAB
Genetics and epigenetics of Type 2 Diabetes physiology
2M€
Cerrado
SAF2011-27086
REGULACION EPIGENETICA DE LAS CELULAS BETA Y DIABETES
436K€
Cerrado
GENETICS OF T1D
Using gene to phenotype studies to identify type 1 diabetes...
50K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Type 2 diabetes (T2D) represents a major challenge to global health. In recent years, over 60 genetic loci have been confidently implicated in T2D predisposition: however, there has been only limited progress in defining the biological mechanisms responsible. Recent work led by the host institution has revealed that these T2D-associated loci are substantially enriched for genes whose protein products interact with CREBBP, identifying this transcriptional co-activator as a key node linking processes involved in T2D development. The research I propose to conduct aims to explore the overall contribution of the CREBBP interactome in T2D predisposition, through integration of existing and novel genetic data. The former is provided by extensive genome wide association (n~100,000 individuals), exome sequence (n~14,000) and exome chip (n~60,000) available to the host institution; the latter will be generated by the applicant through large-scale (>20,000 individuals), targeted resequencing of genes coding for key CREBBP-interacting proteins. Through these data, I expect to generate a comprehensive evaluation of the genetic evidence linking CREBBP-interacting proteins to T2D pathogenesis, laying the foundation for further functional studies. As well as the intrinsic scientific merit of this proposal, the research outlined will provide extensive training in state-of-the-art experimental and analytical methods in human genetics